Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Published:2018-05-31 Issue:22 Volume:378 Page:2078-2092
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Gandhi Leena¹,Rodríguez-Abreu Delvys¹,Gadgeel Shirish¹,Esteban Emilio¹,Felip Enriqueta¹,De Angelis Flávia¹,Domine Manuel¹,Clingan Philip¹,Hochmair Maximilian J.¹,Powell Steven F.¹,Cheng Susanna Y.-S.¹,Bischoff Helge G.¹,Peled Nir¹,Grossi Francesco¹,Jennens Ross R.¹,Reck Martin¹,Hui Rina¹,Garon Edward B.¹,Boyer Michael¹,Rubio-Viqueira Belén¹,Novello Silvia¹,Kurata Takayasu¹,Gray Jhanelle E.¹,Vida John¹,Wei Ziwen¹,Yang Jing¹,Raftopoulos Harry¹,Pietanza M. Catherine¹,Garassino Marina C.¹

Affiliation:

1. From NYU Perlmutter Cancer Center, New York (L.G.); Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria (D.R.-A.), Hospital Universitario Central de Asturias, Oviedo (E.E.), Vall d’Hebron University, Vall d’Hebron Institute of Oncology, Barcelona (E.F.), and Fundación Jiménez Díaz (M.D.) and Hospital Universitario Quirón Madrid (B.R.-V.), Madrid — all in Spain; Karmanos Cancer Institute, Detroit (S.G.);...

Funder

Merck

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1801005

Cited by 4506 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A tumor on a chip for studying immune-cell infiltration into tumor under chemo/immunotherapy treatments;Sensors and Actuators B: Chemical;2024-05

2. Immunotherapy for non-small cell lung cancer;Respiratory Investigation;2024-03

3. Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab;Lung Cancer;2024-03

4. Bilateral optic neuritis attributed to Pembrolizumab: A case report;Current Problems in Cancer: Case Reports;2024-03

5. First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations;European Journal of Cancer;2024-03